Exscientia (EXAI)
(Delayed Data from NSDQ)
$5.22 USD
+0.11 (2.15%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $5.22 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
EXAI 5.22 +0.11(2.15%)
Will EXAI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EXAI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EXAI
Amazon (AMZN) Expands AWS Clientele With Exscientia Deal
How Much Upside is Left in Exscientia (EXAI)? Wall Street Analysts Think 61.43%
EXAI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Exscientia (EXAI) Climb 57.17% to Reach the Level Wall Street Analysts Expect?
Exscientia (EXAI) Upgraded to Buy: Here's What You Should Know
Brian's Big Idea on Healthcare
Other News for EXAI
Analysts Offer Insights on Healthcare Companies: Danaher (DHR), Silence Therapeutics (SLN) and Exscientia Plc (EXAI)
Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
Exscientia Secures Full Rights to Novel Cancer Drug
Exscientia pays GT Apeiron $10M upfont cash+ equity for 'full control' of 617
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD